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Abstract
Background:  Second generation antipsychotics (SGA) have demonstrated several advantages over first
generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower
propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with
causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional
study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non -
treated control patients.
Methods: The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study
subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone,
quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric
history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in
Bologna as a reference group. We investigated differences among the treatment and reference groups for
glycaemia, cholesterolaemia and triglyceridaemia levels.
Results: The study sample was composed of 76 patients, 38 males and 38 females. The reference group was
composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and
triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia
than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels
among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity
than patients treated with other SGAs.
Conclusion: The rate of obesity and metabolic disorders observed in this study were higher than the prevalence
in the control group and similar to that previously reported in psychiatric samples; these findings imply per se that
more attention should be paid to the metabolic condition of psychiatric patients. In line with the International
Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and
triglyceride levels be obtained in routine clinical practice with all antipsychotics.
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Background
In the last decade, second generation antipsychotics
(SGA) have shown several advantages over first genera-
tion antipsychotics (FGA) in terms of positive, negative,
cognitive, and affective symptoms and a lower propensity
for extrapyramidal side effects [1,2]. Despite these unde-
niable advantages, SGA have been associated with causing
and exacerbating metabolic disorders, such as weight
gain/obesity, diabetes, and hyperlipidaemia [3-6]. Hyper-
lipidaemic effects include both hypertriglyceridaemia and
hypercholesterolaemia, although relatively greater effects
may be seen in triglyceridaemia [5,6]. Overweight, hyper-
glycaemia and hyperlipidaemia are risk factors for cardio-
vascular events, such as myocardial infarction and stroke,
and are especially relevant in patients with schizophrenia
because they tend to exhibit other major risk factors such
as smoking and a sedentary lifestyle [4,7]. Moreover, it has
been reported that weight gain is one of main side effects
that will cause patients to discontinue treatments, thus
exposing patients with schizophrenia to an increased risk
of relapse [3,7].
Since most SGA have similar efficacy, side effect profiles
become crucial when choosing treatment. According to a
recent US consensus statement [3], the SGA vary in their
propensity to cause obesity, hyperglycaemia and hyperli-
pidaemia, with clozapine and olanzapine showing the
greatest effects, risperidone and quetiapine having inter-
mediate effects, and aripiprazole and ziprasidone having
lower effects. On the other hand, European [8] and Aus-
tralian [9] consensus statements did not recognize any dif-
ference among SGA as to their propensity to cause
metabolic side effects. Moreover, the American consensus
statement itsel acknowledges the caveat that aripiprazole
and ziprasidone have fewer long-term data due to the lim-
ited amount of time they have been on the market [3].
The present cross sectional study aims to evaluate the met-
abolic risk factor profile of outpatients with mental disor-
ders treated with SGA in the everyday clinical practice of a
Community Mental Health Centre (CMHC) in Bologna,
and to compare this study population with a reference
group of un-treated non-psychiatric outpatients.
Method
This was an open-label, cross-sectional study carried out
from January 2005 to May 2005 at a Community Mental
Health Centre (CMHC) in Bologna with a catchment area
of about 60,000 people. Subjects for the present study
were outpatients with serious mental disorders on main-
tenance treatment with the SGA available in Italy in 2005
(clozapine, olanzapine, risperidone, quetiapine). Since
no formal exclusion criteria were applied, all patients
treated with SGA were eligible for the study. Informed
consent was obtained from the patients. This study was
performed with the approval of the Bologna University
ethics committee, in compliance with the Helsinki Decla-
ration.
Assessment
Clinical records were used for psychiatric diagnoses
according to DSM IV [10] criteria. Patients' socio-demo-
graphic, clinical and treatment information (current
antipsychotic, doses and duration of treatment; previous
antipsychotic treatment; psychotropic drugs with poten-
tial metabolic side effects and any other drug that might
affect glucose or lipid homeostasis) was collected using an
ad hoc schedule.
Assessments for the present analyses included fasting
blood samples for glucose, cholesterol and triglycerides.
The metabolic fasting sample was drawn between 8 and
10 a.m., after at least 8 hours' fasting, before medication
administration. Plasma glucose, cholesterol and triglycer-
ide levels were determined by enzymatic procedure apply-
ing the Roche/Hitachi Modular D-P automated chemistry
analyzer and using the standard analytical system packs
Glucose/God-pap, Cholesterol/CHOD cod-pap and Trig-
lycerides/GPO-pap.
Weight, height and BMI were determined. Body mass
index was computed as body weight (kg) divided by the
square of height (m2). Height and weight for each patient
in the study group were measured by CMHC nurses at the
time of blood examination.
Reference group
A reference group of adult men and women without any
psychiatric history or antipsychotic treatment were ran-
domly selected from outpatients suffering from hyperhy-
drosis and referred to the Department of Neurological
Sciences in Bologna. Fasting plasma glucose, cholesterol
and triglyceride levels were derived anonymously by chart
review of these reference subjects. BMI was not available
in the reference group, but the clinical charts reported if
patients were overweight or obese or not. Thus it was
known from the clinical charts that none of the patients in
the reference group was overweight or obese.
Statistical analyses
We used analysis of variance (ANOVA) to examine differ-
ences among the treatment groups and reference group in
mean glycaemia and cholesterolaemia levels and to com-
pare mean BMI levels among treatment groups. Since trig-
lyceride levels were not normally distributed, median
trigliceridaemia levels were compared among groups,
using non parametrical analysis (Kruskal Wallis test).
At a second stage, by way of co-variants in ANCOVA anal-
ysis we included the sociodemographic variables whichBMC Psychiatry 2006, 6:11 http://www.biomedcentral.com/1471-244X/6/11
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differed among groups. Alpha levels were considered sig-
nificant when below 0.01 (Bonferroni corrected: 0.05/5
groups).
To compare the prevalence of hyperglycaemia, hypercho-
lesterolaemia and hypertriglyceridaemia among groups
we used chi square analysis and the Fisher exact text. We
calculated the crude and adjusted Odds Ratio (OR) to
evaluate the relative risk of hyperglycaemia, hypercholes-
terolaemia and hypertriglyceridaemia for SGA-treated
patients compared to the reference group. At a later stage
we calculated the crude and adjusted Odds Ratio (OR) of
metabolic disorders for SGA-treated patients without
schizophrenia, obesity or over-protracted SGA treatment,
since these conditions were described as risk factors for
metabolic disorders and could thus be confounding fac-
tors in our analysis [11-14].
Abnormal metabolic levels and BMI were defined in our
study on the basis of the National Cholesterol Education
Program (NCEP) [15] and World Health Organisation
(WHO) [16] criteria as follows: 1) an abnormal BMI was
defined as between 25 and 29.9 for overweight and equal
to or greater than 30 for obesity; 2) an abnormal blood
glucose level was defined as equal to or greater than 110
mg/dl (equal to or greater than 126 mg/dl for diabetes);
3) an abnormal blood cholesterol level was defined as
equal to or greater than 200 mg/dl; 4) an abnormal blood
triglyceride level was defined as equal to or greater than
150 mg/dl.
Finally we evaluated the Pearson bi-variate correlations
between metabolic parameters and drug doses. For the
whole analysis we used Statistica for Windows (Statsoft,
Kernel Release 5.5).
Results
Demographic and clinical data
Table 1 shows the sociodemographic, clinical and treat-
ment features of the study sample and of the reference
group. Seventy-six patients were on maintenance treat-
ment with SGA in the index period and all of them con-
sented to receiving fasting blood glucose, cholesterol and
triglyceride evaluations. This study sample was composed
of 76 patients, 38 males and 38 females. The reference
group was composed of 36 subjects, 19 females and 17
males. The psychiatric patients had a mean age of 44.6 ±
16, while the control group had a mean age of 37.3 ± 8.6
(post hoc treatment groups vs reference group: df 1,110, F
6.39, p = 0.0129). As expected, a large majority of the
patients treated with SGA suffered from schizophrenia or
other psychotic disorders.
Table 1: Demographic and clinical features
Reference
 N = 36
Clozapine 
N = 6
Risperidone
 N = 20
Olanzapine
 N = 31
Quetiapine
 N = 19
Male 17(47.2%) 4 (67.0%) 13 (65.0%) 10 (32.3%) 11 (57.9%)
Age (years)* 37.3 ± 8.6 37.2 ± 4.0 41.4 ± 15.1 47.3 ± 17.8 45.9 ± 15.4
Psychiatric Diagnosis
Schizophrenia and 
other psychotic 
disorders
6 (100%) 15 (75%) 23 (74.2%) 10 (52.6%)
Affective disorders 0 5 (25%) 8 (25.8%) 9 (47.4%)
*df 4(107), F = 2.64, p = 0.038
Table 2: Treatments
Clozapine
 N = 6
Risperidone
 N = 20
Olanzapine
 N = 31
Quetiapine
 N = 19
SGA Medication
Dose (mg) 441.3 ± 142.9 2.7 ± 1.6 10.4 ± 5.8 330.3 ± 300.9
Duration (months) 12.7 ± 12.4 12.8 ± 10.7 9.8 ± 11.5 7.4 ± 3.9
Other treatments with 
metabolic side effects1
3 (50%) 3 (16%) 7 (23%) 5 (26%)
Previous treatment
Naive* 0 10 (50%) 13 (42%) 2 (10%)
SGA** 3 (3%) 3(15%) 6(19%) 11 (58%)
FGA 3 (11%) 7 (35%) 12 (39%) 6 (32%)
1Other treatments with metabolic side effects were first generation antipsychotics, carbamazepine, lithium, sodium valproate, mirtazapine.
*chi-sq 11.7, df 3, p = 0.009
** chi-sq 11.5, df 3, p = 0.009BMC Psychiatry 2006, 6:11 http://www.biomedcentral.com/1471-244X/6/11
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Treatment distribution
Table 2 reports the treatment characteristics of the study
sample. Patients in the 4 treatment groups had a similar
duration of SGA exposure: 77% were treated for less than
one year (on average for six months), and the remaining
23% for more than one year. Treatment duration longer
than one year showed a a differing distribution trend
among treatment groups (risperidone n = 8, 42%; clozap-
ine n = 2, 33%; olanzapine n = 5, 16%; quetiapine n = 2,
10.5%; chi-square = 6.8, df = 3, p = 0.077); post hoc analy-
sis showed that significantly more patients treated with
risperidone had a treatment duration longer than one year
compared with other treatment groups (42% of patients
treated with risperidone vs 16% of patients treated with
other SGA, chi-sq = 5.5, df = 1, p = 0.019). Dosages were
at the lower end of the normal range. The distribution of
co-therapies with possible metabolic side effects did not
differ among the four treatment groups. A significantly
higher rate of patients with quetiapine were treated with
SGA in the past and a lower proportion were drug naïve
(table 2) compared with patients in other treatment
groups. None of the patients in the treatment or reference
groups was treated with hypoglycaemic or hypolipidae-
mic agents or other drugs that might affect glucose or lipid
homeostasis.
Relationship between metabolic disorders and treatment
Table 3 shows the mean values of glycaemia, cholestero-
laemia, triglyceridaemia and BMI. Differences among
groups were evaluated including as co-variants age, previ-
ous treatment and treatment duration longer than one
year, which differed among groups. A trend towards a sig-
nificant difference in glucose mean levels was observed (p
= 0.026) and post hoc analysis showed that the reference
group had significantly lower glycaemia (df 1,107, F =
7.95, p = 0.006). Cholesterol mean levels were pathologi-
cal in all groups and did not differ among groups. The trig-
lyceride levels were non-normally distributed; thus we
used non parametric analysis (median and Kruskal Wallis
test). Median triglyceride levels were pathologic in the
clozapine and quetiapine groups. We observed statisti-
cally significant differences in median triglyceridaemia
among groups (p = 0.001); post hoc analysis highlighted
that the reference group had significantly lower triglyceri-
daemia (df 1,112, H = 7.47, p = 0.006). We observed that
mean BMI values were over the clinical threshold of over-
weight in all groups and over the clinical threshold of
obesity in the clozapine group. BMI mean values differed
among groups (p = 0.005); post hoc analysis revealed that
patients with clozapine had a significantly higher BMI (df
1,69, F = 8.18, p = 0.006).
Table 4 shows pathological cases in each group. Hypergly-
caemia prevalence showed a trend towards significant dif-
ference among groups; post hoc analysis showed that as a
whole patients treated with SGA had a trend towards
higher prevalence of hyperglycaemia than the references
group (chi-sq = 5.15, df = 1, p = 0.02; Fisher exact text p =
Table 3: Metabolic profile
Reference 
N = 36
Clozapine 
N = 6
Risperidone 
N = 20
Olanzapine 
N = 31
Quetiapine 
N = 19
df F(H) P
Glucose* (mg/dl) 85.8 ± 10.3 99.67 ± 14.5 95.2 ± 18.6 91.4 ± 14.1 97.2 ± 15.7 4(105) 2.9 0.026
Cholesterol* (mg/dl) 209.3 ± 39.1 223.0 ± 45.9 213.4 ± 41.2 215.8 ± 41.9 237.6 ± 46.9 4(105) 1.3 0.277
Triglycerides**(mg/dl) 75(60.122) 194.5 (108–205) 145 (108–207) 105 (84–143) 161 (92–244) 4(110) 18.9 0.001
BMI 35.3 ± 6.4 29.1 ± 5.9 26.7 ± 5.3 29.3 ± 5.2 3(69) 4.6 0.005
* Means values adjusted fro age and previous treatments are given for glucose and cholesterol (Anova analysis);
** Unweighted median values, first and last quartile are given for triglycerides.(Kruskal Wallis: df 4(110), H = 18.9 p = 0.0008)
Table 4: Pathological cases
Reference 
N = 36
Clozapine 
N = 6
Risperidone 
N = 20
Olanzapine 
N = 31
Quetiapine 
N = 19
chi-
s
d
f
P
Hyperglycaemia 
(110 ≤ glycaemia ≤ 125.9 mg/dl)
1 (3%) 2 (33%) 2 (10%) 2(7%) 4 (22%) 8.9 4 0.06
Diabetes (glycaemia ≥126 mg/dl) 1(5%) 2(6.5%) 1(5%) 2.6 4 0.6
Hypercholesterolemia 
(cholesterolemia ≥200 mg/dl)
22 (61%) 4 (67%) 10 (50%) 18 (58%) 16 (84%) 5.5 4 0.241
Hypertriglyceridemia 
(triglyceridemia ≥150 mg/dl)
5  ( 1 4 % )5  ( 8 3 % )9  ( 4 5 % )7  ( 2 3 % )1 0  ( 5 3 % ) 1 8 . 2 4 0.001
Overweight (25 ≤ BMI ≤ 29.9) 1 (17)% 7 (39%) 13 (42%) 11 (58%) 4.5 3 0.2
Obesity (BMI≥ 30) 5 (83%) 7 (39%) 6 (19%) 6 (32%) 15.8 3 0.015BMC Psychiatry 2006, 6:11 http://www.biomedcentral.com/1471-244X/6/11
Page 5 of 8
(page number not for citation purposes)
0.076). Of the patients with hyperglycaemia, none of the
reference subjects and 4 SGA-treated patients (2 patients
with olanzapine, 1 with risperidone and 1 with quetiap-
ine) reached the glycaemia threshold of diabetes (126 mg/
dl). The prevalence of hypercholesterolaemia did not dif-
fer among groups. The hypertriglyceridaemia rate differed
significantly among groups; post hoc analysis showed that
the prevalence of hypertriglyceridaemia was significantly
greater in SGA-treated patients than in the reference group
(chi-sq = 7.26, df = 1, p = 0.007; Fisher exact text p =
0.003). Treatments groups had a significantly different
rate of obesity (p = 0.015); post hoc analysis showed that
patients on clozapine had a significantly higher rate of
obesity (clozapine n 5, 83%, others n 19, 27%; chi-sq
8.09, df = 2, p = 0.013; Fisher exact text p = 0.012). The
rate of overweight did not differ among treatment groups
(p = 0.2).
The Odds Ratio (OR) of having a diagnosis of hypergly-
caemia was 8 times significantly greater for patients
treated with SGA than for the reference group (OR 7.90,
95%CI 1.00–62.70, p = 0.023); this risk, when adjusted
for age, was still higher in SGA-treated patients (OR 6.12,
95%CI 0.75–49.73, p = 0.09). Moreover the odds of
receiving a diagnosis of hypertriglyceridaemia was 4 times
significantly higher for patients treated with SGA than for
the reference group (OR 4.00, 95%CI 1.39–11.46, p =
0.007); this risk was not affected by adjusting for age (OR
4.00, 95%CI 1.39–11.46, p = 0.007). The OR of receiving
a diagnosis of hypercholesterolaemia was not greater for
SGA-treated patients than for the reference group (OR
1.09, 95%CI 0.48–2.49, p = 0.834). The higher risk of
receiving a diagnosis of hyperglycaemia and hypertriglyc-
eridaemia for SGA-treated patients compared to reference
subjects decreased slightly when considering only the sub-
group of patients without obesity or overweight and did
not decrease for the subgroup of patients without a diag-
nosis of schizophrenia and treatment duration shorter
than one year (data available on request).
Finally Pearson's correlation between SGA doses and
study variables (BMI, glycaemia, triglyceridaemia and
cholesterolaemia) was not significant (data available on
request).
Discussion
Our main findings are that all groups treated with SGA
had a poorer metabolic profile – in particular, signifi-
cantly higher mean glycaemia and triglyceridaemia than
the reference group – while we did not find differences in
mean glycaemia or mean triglyceridaemia levels among
treatment groups. Patients treated with SGA have a 6 times
higher risk of receiving a diagnosis of hyperglycaemia and
a 4 times higher risk of receiving a diagnosis of hypertrig-
lyceridaemia than the control group.
Despite the limitations of this small cross-sectional study,
our findings are consistent with previous evidence in the
literature, which suggests that patients treated with SGA
may be at increased risk of hyperlipidaemia and hypergly-
caemia than untreated people [15-22]. Although several
studies suggest that such rates probably vary among spe-
cific antipsychotic drugs, our study did not find differ-
ences among the various treatment groups. However, we
should consider that at present these differences are not
well quantified. Using a general practice research database
in the United Kingdom, Koro and colleagues [15,16] esti-
mated the risk of hyperlipidaemia and diabetes associated
with olanzapine to be 4.6 (95% CI 2.4–8.9) and 5.8 (95%
CI 2.0–16.7) times the risk associated with no antipsy-
chotic use. In this study supported by Bristol Myers, the
risk associated with risperidone was much lower, at 1.1
(95% CI 0.6–2.1) and 2.2 (95% CI 0.9–5.2) times the risk
associated with no antipsychotic use. In contrast, the
study by Buse et al. [19], supported by Eli Lilly, using a
prescription claims data base in the United States, found
that the risk of diabetes associated with olanzapine (HR
3.0, 95% CI 2.6–3.5), clozapine (HR 3.3, 95% CI 1.4–
8.0), as well as risperidone (HR 3.4, 95%CI 3.1–3.8) and
quetiapine (HR 1.7, 95% CI 1.2–2.4), were higher than
the risk associated with no antipsychotic use.
To our knowledge, among previous cross-sectional clini-
cal studies which evaluated the mean glycaemia level in
patients treated with SGA, only 2 carried out a comparison
with untreated subjects [23,24]. Consistently with our
results, these studies found that treated patients had a sig-
nificantly higher fasting glycaemia level than control sub-
jects; furthermore, again consistently with our study, such
research did not find any significant differences among
patients treated with different SGA (olanzapine, risperi-
done and clozapine) on the fasting glycaemia mean level.
In turn, the Smith et al. study found that in patients
treated with risperidone, olanzapine and clozapine mean
fasting glucose was within the normal range and did not
significantly differ across the drug treatment groups [25].
Among cross-sectional studies which evaluated fasting
triglyceridaemia, only the Alméras et al. study, supported
by Janssen [23], performed a comparison with untreated
subjects. In contrast with our result, this study found dif-
ferences among SGA and showed that olanzapine-treated
patients, but not patients with risperidone, had a higher
triglyceride level. Again, we did not observe a worse cho-
lesterol profile in SGAs-treated patients compared to
untreated subjects, consistently with studies suggesting
that SGA have a relatively greater effect on blood triglycer-
ides than on cholesterol levels [4-6]. Finally, we observed
a higher BMI mean value in patients with clozapine than
in those with 1st line SGA. Although our result should be
regarded carefully, since only 6 patients were treated with
clozapine in our sample, this finding is in accordance withBMC Psychiatry 2006, 6:11 http://www.biomedcentral.com/1471-244X/6/11
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those of other clinical studies which showed the high
impact of clozapine on body weight [11,26-35], as well as
with the results of the Allison meta-analysis [36]. How-
ever, prospective clinical studies comparing different SGA
indicate that weight gain induced by olanzapine is no less
important than clozapine-induced weight gain
[28,34,37,38], and greater than weight gain induced by
other first line SGA (risperidone, quetiapine and ziprasi-
done), as recently shown by the CATIE trial [39].
In accordance with the data in the literature [11,26-28],
we did not find any positive correlations between mean
metabolic and BMI levels and SGA doses, which in our
sample were towards the lower end of the normal range.
Furthermore, in our study patients with shorter duration
of SGA exposure had a similar risk of hyperglycaemia and
hypertriglyceridaemia to that of the overall patient sam-
ple. These results are consistent with various evidence sug-
gesting that SGA metabolic side-effects arise
independently of treatment doses and duration
[11,28,29]. Finally, our results showed that even SGA-
treated patients without other known risk factors for met-
abolic disorders, such as obesity and schizophrenia, had a
higher risk of hyperglycaemia and hypertriglyceridaemia
than the control group. These results are consistent with
several studies which observed SGA metabolic side-effects
even in patients without any weight gain [30] and affected
by mood disorders [31].
All in all, the evidence from published studies in the liter-
ature is not consistent as to the metabolic impact of differ-
ent SGA. We found differing position statements even
among expert Consensus Conferences: while the Ameri-
can Psychiatric Association distinguishes between SGA at
higher and lower risk of causing metabolic side-effect [3],
the Dublin Consensus Conference [8] and the Australian
Consensus Conference [9] are more guarded and con-
clude that each SGA should be viewed with caution con-
cerning its metabolic side-effects. Moreover, several
studies claim that FGA as well, and severe mental disor-
ders  per se, increase the risk of metabolic disorders
[12,13,19,22]. Since the risk of disturbances to both the
glucose and the lipid metabolism and the risk of weight
gain appear to be increased by all antipsychotic treat-
ments and hard to differentiate among the various differ-
ent SGA, according to the international consensus
conferences [3,8,9] we recommend that monitoring of
weight, fasting plasma glucose cholesterol and triglyceride
levels should be performed in routine clinical practice
with all antipsychotics.
Limitations
The most important limitations of our study are due to the
small sample size and the cross-sectional design. The
small sample size may not have allowed us to clarify all
possible differences among treatment groups. The cross-
sectional study design did preclude determination of the
temporal relationship between the prescription of SGA
and the development of obesity and metabolic disorders.
Thus the limitation due to the cross-sectional nature of
this study makes it difficult to understand if these disor-
ders are due to SGA itself or to other risk factors for diabe-
tes mellitus and other metabolic disorders which are
frequently observed in psychiatric patients, such as poor
overall physical health, unhealthy life style, inadequate
health care, familial and genetic vulnerability [40-42].
The lack of matching with the control group in terms of
body composition, and the dearth of background varia-
bles available, limit the information that can be gleaned
from such a comparison. We cannot assume that our con-
trol group is representative of the general population,
since this sample was drawn from hyperhydrotic patients.
Nevertheless, in our experience there is no evidence that
patients suffering from idiopathic hyperhydrosis are at
higher risk of diabetes or dyslipidaemia than the general
population. In our sample SGA-treated patients were sig-
nificantly older than the reference group. However, co-
varying for age we found that age did not influence our
results. This result is consistent with several studies report-
ing that age did not influence the risk of SGA metabolic
disorders, which also occur in young patients [20,43].
Finally our results are limited by lack of information
about some indexes of metabolic disorders, such as fat
distribution and blood pressure, and other important
clinical variables, such as the severity of psychiatric illness.
The relative level of risk associated with each type of SGA
cannot be clearly defined by our cross-sectional study
design. Only 25 (33%) patients were drug naïve before
starting the studied treatment, while 23 patients (30%)
had been treated in the past with different SGA and 28
(37%) with FGA. We should bear in mind that patients
may have been switched from a previous antipsychotic
following the development of obesity or metabolic disor-
ders. Although we cannot rule out this potentially con-
founding variable, we have attempted to adjust for it by
co-varying the effect of previous treatment. This did not
change the results.
Finally we could not calculate the Relative Risk of devel-
oping metabolic disorders of SGA-treated patients as com-
pared to FGA-treated patients, in view of the lack of FGA-
treated patients in our sample.
Conclusion
The health implications of long-term therapy with SGA
that increase the risk of medical morbidity are of growing
concern and may well be more dangerous than the
extrapyramidal symptoms typically associated with olderBMC Psychiatry 2006, 6:11 http://www.biomedcentral.com/1471-244X/6/11
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antipsychotic agents [6,40,41]. As a group, they are much
more expensive than FGA, some of which are available as
generic drugs. Unfortunately, at present independent
studies clearly defining the metabolic risk factor profile
associated with SGA use are thin on the ground and their
findings are often inconsistent.
The rate of obesity and metabolic disorders observed in
the current independent study was higher than the preva-
lence in our control group and in the general population
as reported by epidemiological studies [44,45]. Further-
more this result is consistent with the prevalence found in
extensive studies of psychiatric samples [36,46,47]. These
findings implied per se that more attention should be paid
to the metabolic condition of the psychiatric patients and
that SGA treatment should be monitored routinely in clin-
ical practice. In line with the International Consensus
Conferences [3,8,9], we recommend that monitoring of
weight, fasting plasma glucose levels, cholesterol and trig-
lycerides be included in routine clinical practice with all
antipsychotics. Considering the early emergency of meta-
bolic side effects, this check-up should be done at the
baseline and after the first month of treatment. After the
initial period, evaluation of the metabolic side effects
should be obtained every 6 months during the first year of
treatment and then yearly. Moreover, as International
Consensus Conferences have recommended [3,8,9], clini-
cians should consider any personal and family risk factors
of obesity and metabolic disorders in patients treated with
antipsychotic agents, such as a family history of diabetes.
Particular efforts should be made to implement counsel-
ling about patients' lifestyles and behaviours, which could
potentially limit the antipsychotic metabolic side-effects
[48].
In a society in which cardiovascular disease continues to
be a principal cause of morbidity and mortality, clinicians
need to be aware of the metabolic risk factors when treat-
ing patients with mental disorders, and should weigh the
pros and cons of an antipsychotic drug from each group,
FGA and SGA, evaluating the relative benefits, risks and
cost associated with specific choices.
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